1/2: UHCOP-DLDCCC alliance: Cancer drug discovery/development and education

1/2：UHCOP-DLDCCC 联盟：癌症药物发现/开发和教育

• 批准号: 9789209
• 负责人: Diana S-L. Chow
• 金额: $ 27.88万
• 依托单位: UNIVERSITY OF HOUSTON
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-20 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9789209
• 关键词: Address; Administrator; Advisory Committees; African American; Antineoplastic Agents; Applications Grants; Awareness; Cancer Biology; Cancer Burden; Cancer Center Planning Grant; Cancer Survivorship; Cessation of life; Chemistry; Cities; Clinical; Clinical Trials; Communities; Complement; Comprehensive Cancer Center; Core Facility; DNA; Data; Development; Diagnosis; Education; Education Projects; Education and Outreach; Educational Curriculum; Ensure; Ethnic group; Exhibits; Funding; Future; Genome; Goals; Grant; Health; Hispanic Americans; In Vitro; Incidence; Infrastructure; Institution; Joints; Lead; Libraries; Malignant Neoplasms; Medical center; Medicine; Mentors; Methylation; Mus; Patients; Peptoids; Pharmacologic Substance; Pharmacy Faculty; Pharmacy facility; Pilot Projects; Population; Population Group; Prevalence; Primary carcinoma of the liver cells; Program Development; Proteins; Records; Research; Research Personnel; Research Project Grants; Resistance; Students; Technology; Texas; Time; Training; Training and Education; Transcription Coactivator; United States; United States National Institutes of Health; Universities; anticancer research; cancer health disparity; cancer therapy; career; college; design; drug development; drug discovery; education research; experience; genome wide methylation; graduate student; health disparity; hormone therapy; in vivo evaluation; inhibitor/antagonist; innovation; lectures; malignant breast neoplasm; meetings; member; methylation pattern; multidisciplinary; new technology; novel; outreach; prognostic; programs; research and development; small molecule inhibitor; success; training opportunity; treatment trial; undergraduate research; undergraduate student

SUMMARY OF P20 APPLICATION Our University of Houston College of Pharmacy (UHCOP)-Dan L. Duncan Comprehensive Cancer Center (DLDCCC) alliance will develop the infrastructure for a joint drug discovery/development research program to treat cancers with a health disparity and a joint Cancer Research Education Program (CREP). This alliance is built on complementary expertise in cutting-edge cancer drug discovery technologies at DLDCCC/Baylor College of Medicine (BCM) and in development of cancer drugs at UHCOP. The UHCOP is a constituent of the University of Houston (UH), which is an institution serving underserved health disparity populations (ISUPS). UHCOP faculty members bring a unique perspective from an ISUPS, which is complemented by a wealth of pharmaceutical discovery and development experience, existing programs for undergraduate research, and clinical expertise in working with underserved communities. The DLDCCC, an NCI-designated Comprehensive Cancer Center, contributes prominent experience and perspective in current cancer treatments and clinical trials, cutting edge drug discovery technologies and expertise, cancer research core facilities, and existing undergraduate and graduate training and education programs, including those for patients with cancer health disparities. UHCOP and BCM are member institutions of the Texas Medical Center, the largest medical center in the world. The UHCOP/DLDCCC alliance will be led by an Administrative Core, comprised of senior and experienced investigators in drug discovery/development and cancer biology research. The Internal Advisory Committee (IAC), composed of experienced and senior cancer research and/or education experts, will guide the alliance to ensure the successful completion of the proposed goals. The Administrative Core and IAC will serve as mentors to Co-Leaders of pilot projects, the CREP, and participating early-stage investigators and underrepresented (UR) trainees. We have selected two co-developed and collaborative Pilot Projects, from a total of six, to demonstrate the feasibility of the joint infrastructure for drug discovery/development research investigating cancers with health disparities. These pilot projects have strong potential to launch bi-institutional, NIH-funded cancer drug discovery/development programs and create state-of-the-art cancer research training opportunities. We have co-developed a synergistic CREP that will encourage and prepare UR trainees to enter careers in cancer research. Through research experiences, cancer-specific curricula, and education outreach efforts to the UR trainees, the CREP will provide a platform for long-term sustained efforts for enlarging the pipeline of UR trainees in cancer research. The ultimate goal of the UHCOP-DLDCCC alliance will be to support a multiplier effect by developing joint infrastructure in drug discovery/development, education, and novel cancer technologies to target the unmet need of tackling cancer health disparities and generate preliminary data for successful subsequent NCI R-type grant funding.

P20应用综述 我们休斯顿大学药学院(UHCOP)-丹·L·邓肯综合癌症中心 (DLDCCC)联盟将为联合药物发现/开发研究计划开发基础设施，以 治疗有健康差距的癌症和联合癌症研究教育计划(CREP)。这个联盟是 建立在DLDCCC/Bayler在尖端抗癌药物发现技术方面的互补专业知识基础上 医学学院(BCM)和UHCOP的抗癌药物开发。UHCOP是UHCOP的 休斯顿大学(UH)，这是一家服务于服务不足的健康差距人群(ISUPS)的机构。 UHCOP教职员工从ISUPS带来了独特的视角，并得到了丰富的 药物发现和开发经验，现有的本科生研究计划，以及 在服务不足的社区工作方面的临床专业知识。DLDCCC，NCI指定的综合体 癌症中心，在当前的癌症治疗和临床中贡献了突出的经验和前景 试验、尖端药物发现技术和专业知识、癌症研究核心设施和现有 本科生和研究生培训和教育方案，包括为癌症健康患者提供的方案 差距。UHCOP和BCM是最大的医疗中心德克萨斯医疗中心的成员机构 在世界上。UHCOP/DLDCCC联盟将由一个行政核心领导，该核心由高级和 在药物发现/开发和癌症生物学研究方面经验丰富的研究人员。内部咨询 由经验丰富的资深癌症研究和/或教育专家组成的委员会(IAC)将指导 联盟以确保圆满完成拟议的目标。行政核心和IAC将 担任试点项目联合领导人、CREP和参与早期调查人员和 任职人数不足(UR)的受训人员。我们选择了两个共同开发和合作的试点项目， 总共六个，以证明药物发现/开发研究联合基础设施的可行性 调查不同健康状况的癌症。这些试点项目有很强的潜力推出双机构、 NIH资助的癌症药物发现/开发计划和创建最先进的癌症研究培训 机遇。我们已经共同开发了一个协同的CREP，它将鼓励和准备UR学员进入 从事癌症研究的职业。通过研究经验、针对癌症的课程和教育推广 为城市培训学员提供一个长期持续努力的平台，以扩大 UR癌症研究实习生的流水线。UHCOP-DLDCCC联盟的最终目标将是 通过在药物发现/开发、教育和发展方面发展联合基础设施，支持倍增效应 新的癌症技术，针对未得到满足的需求，解决癌症健康差距，并产生 成功获得NCI R型赠款资金的初步数据。